Mallinckrodt Pharmaceuticals

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company’s core strengths include the acquisition and management of highly regulated raw materials, and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
Company Growth (employees)
Chesterfield, GB
Size (employees)
4,500 (est)
Mallinckrodt Pharmaceuticals was founded in 1867 and is headquartered in Chesterfield, GB

Mallinckrodt Pharmaceuticals Office Locations

Mallinckrodt Pharmaceuticals has offices in Chesterfield, Dublin and Hazelwood
Chesterfield, GB (HQ)
Millennium Way
Hazelwood, US
675 James S Mc Donnell Blvd
Dublin, IE

Mallinckrodt Pharmaceuticals Metrics

Mallinckrodt Pharmaceuticals Financial Metrics

Revenue (2015)

£64.2 m

Revenue growth (2014-15), %


Gross profit

£8.8 m

Gross profit margin (2015), %


Net income (2015)

£1.9 m

Market capitalization (28-Apr-2017)

$4.9 b

Closing share price (28-Apr-2017)


Cash (25-Sep-2015)

£403 k
Mallinckrodt Pharmaceuticals's current market capitalization is $4.9 b.
Mallinckrodt Pharmaceuticals's revenue was reported to be £64.2 m in FY, 2015 which is a 3% increase from the previous period.
FY, 2013FY, 2014FY, 2015


£89.7 m£62.6 m£64.2 m

Revenue growth, %


Cost of goods sold

£79.8 m£56.3 m£55.4 m

Gross profit

£9.9 m£6.3 m£8.8 m

Gross profit Margin, %


Operating expense total

£5.8 m£3.8 m£6.8 m

Pre tax profit

£3.8 m£2.4 m£2 m

Net Income

£3 m£1.9 m£1.9 m
FY, 2013FY, 2014FY, 2015


£9.6 m£1.4 m£403 k

Accounts Receivable

£11.1 m£13.4 m£12.4 m

Current Assets

£43 m£50.1 m£53.5 m


£87 k£64 k£44 k

Total Assets

£43.1 m£50.2 m£53.5 m

Accounts Payable

£70 k£67 k£60 k

Current Liabilities

£4.4 m£9.7 m£9.7 m

Retained Earnings

£3 m£1.9 m£1.9 m

Total Equity

£38.6 m£40.5 m£43.9 m

Financial Leverage

1.1 x1.2 x1.2 x
FY, 2013FY, 2014FY, 2015

Income Taxes Paid

(£748 k)(£528 k)(£117 k)

Mallinckrodt Pharmaceuticals Market Value History

Mallinckrodt Pharmaceuticals News

Mallinckrodt Pharmaceuticals Company Life

You may also be interested in